ACTION POTENTIAL VENTURE CAPITAL
GlaxoSmithKline today announced the launch of Action Potential Venture Capital (APVC) Limited, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies. The fundโs first investment will be in SetPoint Medical, a California company considered a trailblazer in creating implantable devices to treat inflammatory diseases. The fund complements the work of GSKโs Bioelectronics R&D unit, which was established in 2012... after a two-year effort to seek out and engage the most promising researchers in this emerging area of science. The name of the fund comes from electrical signals called action potentials that pass along the nerves in the body. Irregular or altered patterns of these impulses may occur in association with a broad range of diseases. GSK believes that miniaturised devices, or bioelectronic medicines, can be designed to read these patterns. The devices could be designed to interface between the peripheral nervous system and specific organs to read, change or generate electronic impulses that help treat disorders as diverse as inflammatory bowel disease or rheumatoid arthritis; respiratory diseases such as asthma and COPD and metabolic diseases including Type 2 diabetes. The field of bioelectronic medicines is in its very early stages. GSKโs ambition, through collaboration with scientists globally, is to have the first medicine that speaks the electrical language of our body ready for approval by the end of this decade.โWe want to help create the medicines of the future and be the catalyst for this work,โ said Moncef Slaoui, chairman of R&D and architect of GSKโs early stage investment strategy. โGSK can play the integrating role that is needed to drive this new type of medical treatment all the way from the bench to the patient and this fund is a key part of our efforts.โ Action Potential Venture Capital intends to build a portfolio of five to seven companies over the next five years. The fund will focus investments in three areas: - New start-up companies that aim to pursue the vision of bioelectronic medicines - Existing companies with technologies that are interacting with the peripheral nervous system through first-generation devices that can stimulate or block electrical impulses - Companies advancing technology platforms that will underpin these treatment modalities Action Potential Venture Capital will be based in Cambridge, Massachusetts and managed by a small, dedicated team. The fund has named Imran Eba as its first partner. Imran will move from GSKโs Worldwide Business Development organisation and work closely with the Bioelectronics R&D unit.
ACTION POTENTIAL VENTURE CAPITAL
Social Links:
Industry:
Finance Venture Capital
Founded:
2013-01-01
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Euro Microsoft Azure DNS Google Google Cloud Amazon Route 53
Similar Organizations
GP Healthcare Capital
GP Healthcare Capital is a venture capital that makes investments in companies based in the biotechnology industry.
Current Employees Featured
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-06-20 | MicroTransponder | Action Potential Venture Capital investment in Series E - MicroTransponder | 53 M USD |
2021-11-17 | Alpheus Medical | Action Potential Venture Capital investment in Series A - Alpheus Medical | 16 M USD |
2021-07-20 | NeuSpera Medical | Action Potential Venture Capital investment in Series C - NeuSpera Medical | 65 M USD |
2021-01-27 | SetPoint Medical | Action Potential Venture Capital investment in Venture Round - SetPoint Medical | 64 M USD |
2020-08-20 | Exo | Action Potential Venture Capital investment in Series B - Exo | 40 M USD |
2020-07-07 | CVRx | Action Potential Venture Capital investment in Private Equity Round - CVRx | 50 M USD |
2019-09-18 | SetPoint Medical | Action Potential Venture Capital investment in Venture Round - SetPoint Medical | 15.7 M USD |
2019-08-09 | CVRx | Action Potential Venture Capital investment in Series G - CVRx | 93 M USD |
2019-07-03 | Axon Therapies | Action Potential Venture Capital investment in Series A - Axon Therapies | N/A |
2019-05-21 | Cala Health | Action Potential Venture Capital investment in Series C - Cala Health | 50 M USD |